Theravance Biopharma, Inc. Increase (Decrease) in Interest Payable, Net
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Interest Payable, Net of -$1.25 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2024-03-01
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2022-12-31 was $0.00.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2022-09-30 was -$1.30M, a 167.92% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2022-06-30 was -$1.85M.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2022-03-31 was $1.90M, a 3.88% increase year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2022 was -$1.25M.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2021 was -$34.00K.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2020 was -$1.69M, a 165.49% decline from fiscal 2019.
- Theravance Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2019 was $2.57M, a 39.76% increase from fiscal 2018.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$1.30M derived: sum of 2 quarters · filed 2024-03-01 | -$3.15M derived: sum of 3 quarters · filed 2024-03-01 | -$1.25M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.15M derived: sum of 2 quarters · filed 2023-11-09 | -$1.25M 10-Q · filed 2023-11-09 | -$3.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $50.00K 10-Q · filed 2022-08-08 | -$1.82M derived: sum of 3 quarters · filed 2022-08-08 | $90.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $1.90M 10-Q · filed 2022-05-06 | $33.00K derived: sum of 2 quarters · filed 2022-05-06 | $1.94M derived: sum of 3 quarters · filed 2022-05-06 | $37.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $40.00K derived: sum of 2 quarters · filed 2022-02-28 | -$1.86M derived: sum of 3 quarters · filed 2022-08-08 | -$34.00K 10-K · filed 2022-02-28 |
| 2021-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $4.00K derived: sum of 2 quarters · filed 2022-08-08 | $1.83M 10-Q · filed 2021-11-08 | $17.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$74.00K 10-Q · filed 2022-08-08 | -$1.89M derived: sum of 3 quarters · filed 2022-08-08 | $198.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.83M 10-Q · filed 2022-05-06 | $13.00K derived: sum of 2 quarters · filed 2022-05-06 | $2.10M derived: sum of 3 quarters · filed 2022-05-06 | -$519.00K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $272.00K derived: sum of 2 quarters · filed 2022-02-28 | -$2.35M derived: sum of 3 quarters · filed 2022-02-28 | -$1.69M 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$532.00K derived: sum of 2 quarters · filed 2021-11-08 | $132.00K 10-Q · filed 2021-11-08 | -$1.78M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.96M 10-Q · filed 2021-08-05 | -$3.87M derived: sum of 3 quarters · filed 2022-02-28 | -$2.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $664.00K 10-Q · filed 2021-05-06 | -$1.25M derived: sum of 2 quarters · filed 2022-02-28 | $565.00K derived: sum of 3 quarters · filed 2022-02-28 | $7.82M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$99.00K derived: sum of 2 quarters · filed 2022-02-28 | $7.15M derived: sum of 3 quarters · filed 2022-02-28 | $2.57M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $9.06M derived: sum of 2 quarters · filed 2020-11-09 | $4.48M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $7.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.67M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$4.58M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $1.84M 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $21.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |